Science AI Journal
Medicine · Research topic

Open research questions in Liver Disease Diagnosis and Treatment

173 unresolved questions extracted from the limitations and future-work sections of 750 Liver Disease Diagnosis and Treatment papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The proposed endocrinology outpatient pathway should be viewed as a starting framework rather than a fixed model. As MASLD/MASH screening moves from guideline statements into routine diabetes care, several issues require further work: electronic automation, multidisciplinary coordination, population-specific thresholds, prospective validation and integration into hospital- level quality improvement. These are not technical details; they will determine whether MASLD/MASH risk stratification becomes a sustainable part of chronic T2DM management. For the pathway to become part of routine diabetes care, it should function as a closed-loop management system rather than a one-time screening algorithm. Automated FIB-4-based screening, second-line fibrosis stratification, hepatology referral, metabolic longitudinal reassessment, quality control and re- intervention, screening must be connected. This model is particularly relevant to real-world studies and hospital-level quality improvement, where success depends not only on detecting high-risk patients but also on completing downstream testing, referral, treatment alignment and follow-up. The proposed closed-loop model is illustrated in Figure 5. Figure 5 presents the pathway as a dynamic clinical system rather than a sequence of isolated tests. Screening begins with automated FIB-4 calculation, but the value of screening depends on completion of FibroScan CAP/LSM or ELF testing in patients with indeterminate or high-risk results. High-risk patients should enter a defined hepatology referral pathway, while metabolic intervention and pharmacological optimization continue in endo- crinology care. Follow-up at 24 and 48 weeks provides an oppor- tunity to reassess weight, glycaemic control, liver enzymes, CAP, LSM, MRI-PDFF when available, and referral adherence. Quality- control indicators can then inform re-screening and the next management cycle.

    Risk stratification of MASLD/MASH in type 2 diabetes: a pragmatic endocrinology outpatient pathway · 2026 · DOI

  • Traditional classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) based on histology or biochemical traits are insufficient to capture this complexity and clinical strategies rely on generalized treatment approaches that may not target to patient heterogeneity.

    Towards Precision Medicine in MASLD: Evolution of Disease Subtyping · 2026 · DOI

  • lie energy including Alkaloids from natural products play a distinct role in addressing MASLD, as their key strengths in their inherent structural complexity and ability to target multiple interconnected pathological pathways. Their polycyclic scaffolds, such as the isoquinoline ring in BER, the aporphine skeleton in NUC, and the zwitterionic group in BET, can simultaneously modulate multiple interrelated pathological nodes, sensing, AMPK NLRP3 inflammasome inhibition, GPX4-mediated ferroptosis defense, and Tj repair. This multi-target engagement precisely addresses the complex pathological network outlined by the current multiple-hit hypothesis of MASLD. Encouragingly, increasingly supported by this mechanistic framework is evidence from translational medicine. Notably, emerging findings this research mechanistic model. For instance, Phase II/III clinical imaging studies have confirmed that BER significantly and reproducibly alleviates hepatic steatosis. Similarly, preclinical studies have demonstrated that NUC and BET improve multiple endpoint indicators, inflammation, and fibrosis. deposition, including validate clinical further from lipid Although natural product alkaloids hold great promise for MASLD therapy, their clinical application is hindered by three core bottlenecks: ambiguous molecular targets, poor oral bioavailability, and a significant gap between animal efficacy and clinical translation. The mechanisms of action for most alkaloids remain confined to descriptive characterizations of downstream signaling pathways, while their direct protein targets remain elusive. This impedes the establishment of SARs and the optimization of target selectivity. Future research should leverage chemical proteomics and biophysical approaches to precisely identify the direct protein targets of these alkaloids. Based on newly identified scaffolds and well-established pathways such as PPARα, PI3K/AKT, and AMPK/Nrf2, systematic SAR studies should be conducted to minimize off-target effects. Furthermore, integrating single-cell transcriptomics, spatial transcriptomics, and lipidomics will facilitate the dissection—at single-cell resolution—of sphingolipid metabolism the differential effects of alkaloids on various hepatic cell subpopulations, as well as their reprogramming effects on pathological ceramides). Concurrently, implementing 3D human hepatocyte spheroids and liver-biliary organoid models will help predict human-specific metabolism and interspecies translational gap.

    An updated overview of alkaloids for the prevention and treatment of metabolic dysfunction-associated steatotic liver disease · 2026 · DOI

  • ABSTRACT Intermittent fasting (IF) ameliorates metabolic dysfunction‐associated steatotic liver disease (MASLD), but the underlying mechanism remains unclear.

    Ahcy Acts as an Effector of Hnf4a‐Driven Super‐Enhancer Activation to Alleviate MASLD During Intermittent Fasting · 2026 · DOI

  • While conventional labora- tory indicators can distinguish CHB from HBV-ACLF, they remain insufficient for accurately stratifying ACLF stages, 1 3Z.

    Characterization of multi-stage metabolic alterations in hepatitis B virus-related acute-on-chronic liver failure using high-coverage metabolomics · 2026 · DOI

  • BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is linked to obesity and cardiometabolic dysfunction, yet local prevalence data from Mexican first-level care units are scarce.

    MASLD prevalence by ultrasonography and clinical profile in obese adults attending a Mexican primary care unit: a cross-sectional study · 2026 · DOI

  • Background and AimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatocellular carcinoma (HCC), particularly in obesity, yet mechanisms linking hepatocyte dysfunction to tumorigenesis remain unclear.

    Hepatocyte MLKL Drives Obesity-Driven Hepatocellular Carcinoma Progression via Mitochondrial Dysfunction Independent of Necroptosis in MASLD · 2026 · DOI

  • 8 VCTE <8 kPa 8-12 kPa >12 kPa Thresholds shown are for advanced fibrosis in MASLD as reported in the body of this review; validated, etiology-specific rule-out/rule-in cut-points for ALD and MetALD are not yet established (see Gaps, Challenges and Future Directions).

    Steatotic Liver Disease: Non-Invasive Assessment and Biomarkers Across MASLD, MetALD and ALD · 2026 · DOI

  • MRI proton density fat fraction (MRI-PDFF) has displaced biopsy as a reproducible biomarker, yet real-world comparative monitoring data and formal early-response prediction remain scarce in Indonesian practice.

    Longitudinal MRI-PDFF Quantification of Hepatic Steatosis Reversibility During SGLT2-Inhibitor versus GLP-1 Receptor Agonist Therapy: A Prospective Cohort Study · 2026 · DOI

  • Nonetheless, some controversies remain to be solved before the wide adoption of such assessment. Whether TE cutoffs established in viral hepatitis populations are directly transferable to MASLD remains debated (Eddowes et al.

    Beyond biochemistry: multiparametric ultrasound parameters and their molecular correlates in cardio-renal-metabolic syndrome · 2026 · DOI

  • BACKGROUND The burden of alcohol-related liver disease in China is becoming increasingly significant, and malnutrition in Chinese patients with alcoholic liver cirrhosis (ALC) is inadequately characterized.

    Clinical assessment of malnutrition among patients with alcoholic liver cirrhosis: A single-center study in Southern China · 2026 · DOI

  • The combined effects of prolonged particulate matter exposure and unhealthy lifestyle behaviors represent important and underrecognized contributors to MASLD progression.

    Combined Lifestyle and Air Pollution Drivers of Liver Injury: A Literature Review · 2026 · DOI

  • Future research should investigate the potential of resmetirom in combination with agents such as GLP-1 receptor agonists, SGLT2 inhibitors, and statins, particularly in light of recent long-term safety data regarding these drug classes and their effects on the thyroid axis.

    A Review on Resmetirom: An Oral Thyroid Hormone Receptor-β Agonist for the Treatment of Metabolically dysfunction-Associated Steatohepatitis (MASH) · 2026 · DOI

  • Although dietary factors may influence MASLD progression, the long-term liver-specific implications of artificially sweetened beverage (ASB) intake remain unclear.

    Artificially sweetened beverage intake and risk of liver-related adverse events in individuals with MASLD: A prospective UK Biobank cohort study · 2026 · DOI

  • However, the underlying molecular processes of the disease are not yet fully understood, which complicates the development of effective pharmaceutical treatments [27].

    Effects of hesperidin, nanohesperidin and obeticholic acid on hepatic FXR and SMAD3 in HFD/fructose-fed mice · 2026 · DOI

  • A limitation of this study is that no information was available on whether blood sampling was performed during the follicular or luteal phase of the cycle of intra- and postpubertal girls, which may have led to increased variability in estradiol concentra- tions in this group. Another limitation of this study is that there were no liver biopsies available for participants.

    Estradiol negatively associates with metabolic dysfunction-associated steatotic liver disease in children · 2026 · DOI

  • With the recent USA approvals of a THR-β agonist (resmetirom) in 2024 and GLP-1R agonist (semaglutide) in 2025 for adults with MASH and moderate-to-advanced fibrosis, the field is shifting from generalized metabolic control toward multi-mechanism targeting and stage-aware, liverselective interventions. Early multi-mechanism approaches are exemplified by the GLP-1R/GIPR/GCGR triple agonist (retatrutide) (Sanyal et al. 2024) and GLP-1R/GCGR dual agonist (survodutide), which extend metabolic debulking beyond GLP-1 monotherapy. Systematic evaluation of combination and sequencing strategies is now a critical priority. Combination strategies may pair upstream metabolic debulking agents (GLP-1 monotherapy, GLP-1R/GCGR dual agonists, and nextgeneration triple agonists) with liver-directed therapies, including THR-β agonists, FXR agonists, FGF21 analogs, and antifibrotic agents that more directly target fibrosis and intrahepatic pathology. Such an approach may facilitate early improvements in body weight, insulin resistance, and steatosis, while subsequently promoting more durable histologic improvements. In addition, a sequential treatment strategy may offer further advantages, whereby initial metabolic debulking establishes a more favorable hepatic environment before introducing agents specifically designed to target activated HSCs, fibrotic lesions, or other intrahepatic drivers of persistent fibrosis. Early clinical signals support GLP-1 + FGF21 strategies under evaluation, informing rational co-administration or sequence designs with prespecified safety architectures (Harrison et al. 2025). Beyond selecting therapeutic mechanisms and treatment sequences, optimizing the delivery of these agents will also be essential for the long-term management of MASH. Given that MASH requires chronic treatment, and that most incretin- and FGF-based therapies are being developed as repeatedly administered subcutaneous injectable formulations, the development of long-acting drug delivery systems (DDSs) may improve treatment durability, reduce dosing frequency, enhance patient adherence, and stabilize systemic exposure. For GLP-1-based therapies, a rapid increase in peak plasma 1 3Journal of Pharmaceutical Investigation concentration resulting from excessive initial burst release may contribute to gastrointestinal adverse events, such as nausea and vomiting. Therefore, sustained-release depot formulations require careful optimization of release kinetics to minimize the initial burst and maintain stable systemic exposure (Kim et al. 2024; Maharjan et al. 2024). Stage-specific selection of liver-targeting strategies is also critical in MASH.

    Emerging metabolic hormone therapeutics for metabolic dysfunction-associated steatohepatitis: incretin-based drugs, fibroblast growth factor analogs, and liver-targeting strategies · 2026 · DOI

  • Both diseases are intertwined by mechanisms such as insulin resistance, adipose tissue dysfunction, and chronic inflammation, though the exact molecular and genetic basis remains unclear. Clinical challenges persist in screening and diagnosing patients, as current non-invasive methods are insufficient for identifying risks of progression from simple steatosis to steatohepatitis and fibrosis. Moreover, effective treatments for both T2DM and NAFLD/MASH are lacking, with therapies mainly targeting T2DM.

    The Bidirectional Relationship Between Type 2 Diabetes and NAFLD/MASH: Pathophysiology, Screening Strategies, and Therapeutic Opportunities · 2026 · DOI

  • MASLD has evolved from a poorly defined entity to the most prevalent chronic liver condition worldwide, imposing a substantial and escalating burden on global health systems.

    Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options · 2026 · DOI

  • While emerging evidence highlights the role of PYROXD2 in mitochondrial redox homeostasis and respiratory chain integrity, its pathological contribution to early-onset liver fibrosis remains poorly characterized, particularly in the context of monogenic metabolic disorders and oxidative stress-mediated hepatocyte injury.

    Early-onset hepatic fibrosis linking to a novel <i>PYROXD2</i> mutation: A case report · 2026 · DOI

  • While a large body of literature has described associations between gut microbiota alterations and MASLD, a critical synthesis of the mechanistic pathways linking microbial activity to liver injury remains lacking.

    The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets · 2026 · DOI

  • ABSTRACT Background and Aims Although spleen stiffness measurement (SSM) via 100 Hz probe shows promise in predicting hepatic decompensation, its prognostic value across different etiological backgrounds remains insufficiently validated.

    Spleen Stiffness Measured by 100‐Hz Probe Predicts Decompensation in Patients With Compensated Advanced Chronic Liver Disease · 2026 · DOI

  • Background The accuracy of Fatty Liver Index (FLI) and Hepatic Steatosis Index (HSI) to predict liver steatosis in people living with HIV (PLWH) remains poorly studied in low- and middle-income countries (LMICs).

    Diagnostic value of serological scores for the detection of liver steatosis in people living with HIV in low- and middle-income countries. · 2026 · DOI

  • Although MVPA and plasma fatty acids have been individually studied in relation to metabolic health, their independent and combined associations with MASLD incidence remain unclear.

    Physical activity, fatty acids, and MASLD risk: Behavioural and metabolic factors jointly shaping liver health in populations · 2026 · DOI

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are strongly linked to cardiac dysfunction, particularly, heart failure with preserved ejection fraction (HFpEF), yet the mechanisms underlying this association remain unclear because robust integrative preclinical models are lacking and the liver and heart are rarely studied as a coordinated system.

    A Translational Model of MASLD-Associated HFpEF Defines Mitochondrial Dysfunction and Cardiac Plasticity During Disease Progression and Regression · 2026 · DOI

Most-cited papers in Liver Disease Diagnosis and Treatment

Most recent work

Find a gap in your own Liver Disease Diagnosis and Treatment sub-topic

This page shows what the Liver Disease Diagnosis and Treatment literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
173 open questions have been extracted from the limitations and future-work passages of 750 Liver Disease Diagnosis and Treatment papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.